BioLineRx Ltd. (BLRX) stock surged by 5.7% at the last trading close while the BLRX stock price continued to rise by 3.24% in the pre-market trading session. BioLineRx Ltd. is an oncology-focused late-stage biopharmaceutical firm. The business strategy of BioLineRx is to in-license novel drugs, improve them across clinical phases, and then collaborate with pharmaceutical firms for further clinical production and/or commercialization.
What is happening?
BLRX revealed on April 15, 2021, that it had submitted a poster at the AACR Annual Meeting, which will be held on a simulated basis from April 10-15, 2021. The poster, titled “A Multi-Center Phase 2a Trial of the CXCR4 Inhibitor Motixafortide (BL-8040) in Combination with Pembrolizumab and Chemotherapy, in Patients with Metastatic Pancreatic Adenocarcinoma, the COMBAT Study,” contains new analyses from the Company’s Phase 2a COMBAT/KEYNOTE-202 triple combination research of motixafortide in metastatic pancreatic cancer.
In the COMBAT/KEYNOTE-202 trial, patients with advanced pancreatic ductal adenocarcinoma, or PDAC, were given BioLineRx’s lead therapeutic candidate, motixafortide, in conjunction with KEYTRUDA® and chemotherapy.
Dr. Abi Vainstein, Chief Medical Officer of BioLineRx said that Liver metastases are a major factor in patients with metastatic PDAC having a bad prognosis. BLRX is delighted to present this additional review, which improves the findings announced from the COMBAT/KEYNOTE-202 trial in December 2020, since not only were nearly all patients diagnosed with stage 4 disease at the outset, but the overwhelming majority (80%) of the patients still had liver metastases, highlighting the study’s exceedingly challenging patient population. These findings should be replicated in a clinical experiment, and BLRX team is already working hard to determine the program’s next steps with future partnership collaborators.